Document is current
Any future updates will be listed below
-
Authors
Ben-Hamo, Rotem
Jacob Berger, Adi
Gavert, Nancy https://orcid.org/0000-0003-1639-4684
Miller, Mendy
Pines, Guy https://orcid.org/0000-0003-2923-660X
Oren, Roni
Pikarsky, Eli
Benes, Cyril H.
Neuman, Tzahi
Zwang, Yaara
Efroni, Sol https://orcid.org/0000-0001-7927-6349
Getz, Gad https://orcid.org/0000-0002-0936-0753
Straussman, Ravid https://orcid.org/0000-0002-9476-329X
-
Funding
Funding for this research was provided by:
Paul C. Zamecnik Chair in Oncology, MGH Cancer Center
Fabrikant-Morse Families Research Fund for Humanity Moross Integrated Cancer Center, and the Rising Tide Foundation
- License Information
-
More Information
Article History
Received: 5 October 2019
Accepted: 12 June 2020
First Online: 3 July 2020
Competing interests
: R.S. and N.G. serve as external consultants to CuResponse and in such context have been issued equity incentives in the company. G.G. receives research funds from IBM and Pharmacyclics. G.G. is an inventor on patent applications related to bioinformatic tools such as MuTect, MutSig, ABSOLUTE, and POLYSOLVER. G.G. is a founder, consultant and holds privately held equity in Scorpion Therapeutics. R.B, G.G. and R.S. are inventors on a patent application related to this work. All other authors declare no competing interests.
